Management of patients with chronic obstructive pulmonary disease in COVID-19 pandemic
https://doi.org/10.33667/2078-5631-2020-19-77-80
Abstract
The pandemic of COVID-19, a disease caused by a novel coronavirus SARS-CoV-2, is associated with significant morbidity and mortality. Recent data showed that patients with chronic obstructive pulmonary disease (COPD) have an increased risk for severity and complicated COVID-19 infection. In coronavirus pandemic, patients with COPD should continue standard maintenance therapy, including bronchodilators and their combination with inhaled glucocorticosteroids, in order to maintain a stable condition and prevent the development of exacerbations that can be provoked by COVID-19. It is important for this group of patients to carefully monitor the condition and follow measures aimed at preventing infection with coronavirus infection due to the increased risk of adverse outcomes.
About the Authors
S. I. Krayushkin
Volgograd State Medical University
Russian Federation
Volgograd
Russian Federation
Volgograd
I. V. Ivakhnenko
Volgograd State Medical University
Russian Federation
Volgograd
Russian Federation
Volgograd
E. A. Sushchuk
Volgograd State Medical University
Russian Federation
Volgograd
Russian Federation
Volgograd
A. V. Zaporoshchenko
Volgograd State Medical University
Russian Federation
Volgograd
Russian Federation
Volgograd
References
1. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020; 12 (7): 6049-6057. https://doi.org/10.18632/aging.103000
2. Jain V., Yuan J.M. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis [published online ahead of print, 2020 May 25]. Int J Public Health. 2020; 1-14. https://doi.org/10.1007/s00038-020-01390-7
3. Lippi G., Henry B. M. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19) Respir Med. 2020; 167: 105941. Published online 2020 Mar 24. https://doi.org/10.1016/j.rmed.2020.105941
4. Long L, Zeng X, Zhang X., Xiao W., Guo E., Zhan W., Yang X., Li C., Wu C., Xu T., Zhan C., Chen Y., Jiang M., Zhong N., Lai K. Short-term outcomes of COVID-19 and risk factors for progression. Eur Respir J. 2020; 55 (5): 2000990. Published 2020 May 27. https://doi.org/10.1183/13993003.00990-2020
5. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2020. [Электронный ресурс]. URL: https://goldcopd.org/gold-reports/ (дата обращения: 20.06.2020)
6. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (2020 update). [Электронный ресурс]. URL: https://ginasthma.org/reports/ (дата обращения: 20.06.2020)
7. Временные методические рекомендации Минздрава России «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)» [Электронный ресурс], версия 7 от 03.06.2020: 175 с. [Temporary guidelines of the Ministry of health of the Russian Federation «Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)», version 7 from 03.06.2020: 175 p]. URL: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf (дата обращения:20.06.2020)
8. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health Last updated June 11, 2020. [Электронный ресурс] URL: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf (дата обращения:20.06.2020)
9. Hoffmann M., Kleine-Wever H., Kruger N., Muller M., Drotsten C., Pholhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry in target cells. Cell. 2020, 181: 1-10. https://doi.org/10.1101/2020.01.31.929042
10. Mehra M.R., Desai S.S., Kuy S., Henry T.D., Patel A.N. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. Online ahead of print 2020 May 1. https://doi.org/10.1056/nejmoa2007621
11. Parohan M., Yaghoubi S., Seraji A., Javanbakht M. H., Sarraf P., Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies [published online ahead of print, 2020 Jun 8]. Aging Male. 2020; 1-9. https://doi.org/10.1101/2020.04.09.20056291
12. Zhao Q., Meng M., Kumar R., Wu Y., Huang J., Lian N., Deng Y., Lin S. The Impact of COPD and Smoking History on the Severity of COVID-19: A Systemic Review and Meta-Analysis. J Med Virol. 2020, 15 April [Epub ahead of print]. https://doi.org/10.1002/jmv.25889
13. Alqahtani J., Oyelade T., Aldhahir A.M., Alghamdi S.M., Almehmadi M., Alqahtani A.S., Quaderi S., Mandal S., Hurst J.R. Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. PLoS One. 2020; 15 (5): e0233147. [Published online 2020 May 11]. https://doi.org/10.1101/2020.03.25.20043745
14. Leung J.M., Yang C.X., Tam A., Shaipanich T., Hackett T., Singhera G.K., Dorscheid D.R., Sin D.D. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. European Respiratory Journal. 2020; 55: 2000688. https://doi.org/10.1183/13993003.00688-2020
15. Brake S.I., Barnsley K., Lu W., McAlinden K.D., Eapen M. S., Sohal S. S. Smoking Upregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19). J. Clin. Med. 2020, 9 (3): 841; [Published: 20 March 2020]. https://doi.org/10.3390/jcm9030841
16. Hurst J.R., Skolnik N., Hansen G.J., Anzueto A., Donaldson G.C., Dransfield M.T., Varghese V. Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life. European journal of internal medicine. 2020; 73: 1-6. https://doi.org/10.1016/j.ejim.2019.12.014
17. Bhutani M., Hernandez P., Bourbeau J., Dechman G., Penz E., Aceron R., Beauchamp M., Wald J., Sticklan M., Olsen S., Goodridge D. Key Highlights of the Canadian Thoracic Society’s Position Statement on the Optimization of COPD Management During the COVID-19 Pandemic [published online ahead of print, 2020 May 16]. Chest. 2020; S0012-3692 (20): 31456-2. https://doi.org/10.1016/j.chest.2020.05.530
18. Halpin D. M.G., Singh D., Hadfield R. M. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. European Respiratory Journal. 2020; 55: 2001009. https://doi.org/10.1183/13993003.01009-2020
19. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Хроническая обструктивная болезнь легких [Электронный ресурс]: Год утверждения (частота пересмотра): 2018 (пересмотр каждые 3 года); ID: КР603; Профессиональные ассоциации: Российское респираторное общество. [Ministry of health of the Russian Federation. Clinical guidelines. Chronic obstructive pulmonary disease. 2018]. URL: http://cr.rosminzdrav.ru/#!/schema/908 (дата обращения: 20.06.2020)
20. Kaye L., Theye B., Smeenk I., Gondalia R., Barrett M. A., Stempel D. A. Changes in medication adherence among patients with asthma and COPD during the COVID-19 pandemic [published online ahead of print, 2020 May 1]. J Allergy Clin Immunol Pract. 2020; S 2213-2198 (20): 30412-8. https://doi.org/10.1016/j.jaip.2020.04.053
21. Айсанов З. Р., Калманова Е. Н., Каменева М. Ю., Кирюхина Л.Д., Лукина О.Ф., Науменко Ж.К., Неклюдова Г.В., Перельман Ю.М., Савушкина О.И., Стручков П.В., Черняк А.В., Чушкин М.И., Шергина Е.А. Рекомендации Российского респираторного общества по проведению функциональных исследований системы дыхания в период пандемии COVID-19 Версия 1.1. от 19.05.2020. [Aisanov Z.R., Kalmanova E.N., Kameneva M. Yu., Kiryukhina L. D., Lukina O. F., Naumenko Zh.K., Neklyudova G.V., Perelmanyu. M., Savushkina O.I., Struchkov P.V., Chernyak A.V., Chushkin M.I., Shergina E.A. Recommendations of the Russian respiratory society for functional research of the respiratory system during the COVID-19 pandemic Version 1.1. from 19.05.2020]. URL: https://spulmo.ru/upload/rekomendacii_rro_fvd_COVID_19_rev1_1_01062020.pdf (дата обращения: 20.06.2020)
22. Авдеев С.Н. Патофизиология обострений хронической обструктивной болезни легких. Вестник анестезиологии и реаниматологии. 2019; 2 (16): 75-82. [Avdeev S.N. Pathologic physiology of exacerbations of chronic obstructive pulmonary disease. Messenger of Anesthesiology and Resuscitation, 2019, 16 (2): 75-82]. https://doi.org/10.21292/2078-5658-2019-16-2-75-82
23. Guan W.J., Ni Z.Y., Hu Y., Liang W., Ou C., He J., Liu L., Shan H., Lei C., Hui D., Du B., Li L., Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382: 1708-1720. https://doi.org/10.1056/nejmoa2002032
24. Tal-Singer R, Crapo JD. COPD at the Time of COVID-19: A COPD Foundation Perspective. Chronic Obstr Pulm Dis. 2020; 7 (2): 73-75. https://doi.org/10.15326/jcopdf.7.2.2020.0149
25. Attaway A. Management of patients with COPD during the COVID-19 pandemic [published online ahead of print, 2020 May 11]. Cleve Clin J Med. June 2020. https://doi.org/10.3949/ccjm.87a.ccc007
Review
For citations:
Krayushkin S.I., Ivakhnenko I.V., Sushchuk E.A., Zaporoshchenko A.V. Management of patients with chronic obstructive pulmonary disease in COVID-19 pandemic. Medical alphabet. 2020;1(19):77-80. (In Russ.) https://doi.org/10.33667/2078-5631-2020-19-77-80
Views:
2722
Email this article 